MINK THERAPEUTICS, INC. (INKT)
$1.76
Insights on MINK THERAPEUTICS, INC.
Vs SGEN
In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 28.6%
Performance
- $1.76$1.97$1.76
0.0%
Downside
Day's Volatility :10.66%
Upside
10.66%
- $0.85$4.32$1.76
51.65%
Downside
52 Weeks Volatility :80.3%
Upside
59.26%
Returns
| Period | MINK THERAPEUTICS, INC. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -15.79% | 0.7% | -6.8% |
6 Months | -32.82% | -8.3% | -6.0% |
1 Year | 17.33% | -1.9% | -4.6% |
3 Years | -85.33% | 25.3% | 25.9% |
Highlights
Market Capitalization | 64.7M |
Book Value | - $0.13 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.76 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -69.76% |
Return On Equity TTM | -403.66% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -29.3M |
Diluted Eps TTM | -0.76 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.74 |
EPS Estimate Next Year | -0.8 |
EPS Estimate Current Quarter | -0.24 |
EPS Estimate Next Quarter | -0.19 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 297.73%
Technicals Summary
Sell
Neutral
Buy
MINK THERAPEUTICS, INC. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 MINK THERAPEUTICS, INC. | 61.47% | -32.82% | 17.33% | -85.33% | -85.33% |
 Moderna, Inc. | -4.27% | -29.63% | -10.94% | 105.39% | 586.61% |
 Regeneron Pharmaceuticals, Inc. | -8.82% | -3.37% | 11.63% | 22.7% | 139.69% |
 Seagen, Inc. | -1.74% | 61.71% | 45.87% | 23.07% | 217.59% |
 Vertex Pharmaceuticals Incorporated | -6.21% | 0.88% | 20.1% | 12.88% | 112.8% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
MINK THERAPEUTICS, INC. | NA | NA | NA | -0.74 | -4.04 | -0.7 | 0.0 | -0.13 |
Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
Vertex Pharmaceuticals Incorporated | 26.15 | 26.15 | 0.41 | 14.62 | 0.26 | 0.17 | 0.0 | 56.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
MINK THERAPEUTICS, INC. | Buy | $64.7M | -85.33% | NA | 0.0% |
Moderna, Inc. | Buy | $49.1B | 586.61% | 11.46 | 31.77% |
Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 139.69% | 19.72 | 33.81% |
Seagen, Inc. | Hold | $36.7B | 217.59% | NA | -31.55% |
Vertex Pharmaceuticals Incorporated | Buy | $83.8B | 112.8% | 26.15 | 35.4% |
Institutional Holdings
Artal Group S A
0.84%Longbow Finance SA
0.49%First Republic Inv Mgmt Inc
0.15%Vanguard Group Inc
0.14%Geode Capital Management, LLC
0.07%StoneX Group Inc
0.05%
Corporate Announcements
MINK THERAPEUTICS, INC. Earnings
MINK THERAPEUTICS, INC.’s price-to-earnings ratio stands at None
Read More
Company Information
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY.
Organization | MINK THERAPEUTICS, INC. |
Employees | 37 |
CEO | Dr. Garo H. Armen Ph.D. |
Industry | Services |
